Tissue-type plasminogen activator-plasminogen-fibrin complex (tPA-PLG-Fibrin complex)

The tissue-type plasminogen activator-plasminogen-fibrin complex is a transient molecular assembly that serves as the primary engine for fibrinolysis in the human vascular system (Longstaff & Kolev, 2015). Within this complex, fibrin acts as a critical cofactor and scaffold, providing binding sites for both the enzyme tissue-type plasminogen activator (tPA) and its proenzyme substrate, plasminogen (UniProt, 2024). The assembly of this ternary complex dramatically accelerates the conversion of plasminogen into the active protease plasmin, which then degrades the fibrin meshwork of a blood clot (StatPearls, 2023). This mechanism ensures that fibrinolysis is localized to the thrombus, preventing widespread systemic proteolysis. In clinical practice, this complex is the pharmacological target for thrombolytic drugs used to treat acute ischemic stroke, myocardial infarction, and pulmonary embolism (NIH, 2023). Drugs like alteplase and tenecteplase are engineered to bind this complex and initiate rapid clot dissolution to restore tissue perfusion. However, the use of these agents is limited by the risk of major bleeding complications, particularly intracranial hemorrhage, if the fibrinolytic activity becomes too systemic (StatPearls, 2023).

Other names

Ternary complex of fibrinolysisFibrin-tPA-plasminogen complexFibrin-bound plasminogen activator complextPA-plasminogen-fibrin ternary complex

Fibrin-specific plasminogen activation